Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial

BACKGROUND: Bevacizumab combined with modified FOLFOX6 is a standard regimen for colorectal cancer. The present study was to determine the efficacy and safety of bevacizumab-modified FOLFOX6 regimen in heavily pretreated patients with human epidermal growth factor receptor 2 (HER2/neu)-negative MBC....

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ting, Wang, Biyun, Wang, Zhonghua, Ragaz, Joseph, Zhang, Jian, Sun, Si, Cao, Jun, Lv, Fangfang, Wang, Leiping, Zhang, Sheng, Ni, Chen, Wu, Zhenhua, Xie, Jie, Hu, Xichun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506015/
https://www.ncbi.nlm.nih.gov/pubmed/26186012
http://dx.doi.org/10.1371/journal.pone.0133133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506015/
https://www.ncbi.nlm.nih.gov/pubmed/26186012
http://dx.doi.org/10.1371/journal.pone.0133133

Ejemplares similares